Treatment device for plasma virus inactivation

Patent metadata

Field	Value
Publication number	US-2016144095-A1
Application number	US-201514946285-A
Country	US
Kind code	A1
Filing date	Nov 19, 2015
Priority date	Nov 20, 2014
Publication date	May 26, 2016
Grant date	—

Abstract

A device and method can be used for clinical virus inactivation treatment to automatically, continuously and cyclically treat plasma of a patient in a closed system. The disclosed plasma treatment device may be used for an anti-viral agent such as, for example, methylene blue photochemical plasma virus inactivation. The plasma treatment device can perform real-time treatment to the plasma in the closed system on the basis of the principle of plasma exchange and can realize real-time back-transfusion during treatment.

First claim

1 . A treatment device for plasma virus inactivation, comprising:
a blood separation device having an input port and an output port, the blood separation device including a mechanism that separates blood into plasma and a remaining portion; a light treatment device having an input port and an output port; a first fluid conduit that fluidly connects the output port of the blood separation device with the input port of the light treatment device so that plasma from the blood separation device can flow to the light treatment device through the first fluid conduit; a first transport pump coupled to the first fluid conduit and configured to pump fluid through the first conduit; a dosing device coupled to the first fluid conduit so that plasma flows through the dosing device as plasma flows from the blood separation device to the light treatment device, wherein the dosing device doses an antiviral agent into the plasma; a second fluid conduit fluidly connected to the outlet port of the light treatment device; a third fluid conduit fluidly connected to the input port of the blood separation device; a second transport pump coupled to the second fluid conduit and configured to pump fluid through the second conduit; and a third transport pump coupled to the third fluid conduit and configured to pump fluid through the third conduit.

2 . The treatment device according to claim 1 , wherein the light treatment device comprises an illumination pipeline and a light source that illuminates the illumination pipeline, and wherein an input port of the illumination pipeline is the input port of the light treatment device, and wherein an output port of the illumination pipeline is the output port of the light treatment device.

3 . The treatment device according to claim 2 , wherein the light treatment device further comprises a box body, and wherein both the light source and the illumination pipeline are located within the box body.

4 . The treatment device according to claim 3 , wherein the light treatment device further comprises a temperature control device that controls a temperature of an internal space of the box body.

5 . The treatment device according to claim 2 , wherein the illumination pipeline comprises at least one of an illumination container and an illumination guide pipe.

6 . The treatment device according to claim 5 , wherein the illumination guide pipe is in a tortuous shape with a plurality of straight segments.

7 . The treatment device according to claim 2 , wherein the illumination pipeline includes an oscillating device.

8 . The treatment device according to claim 1 , wherein the antiviral agent of the dosing device is solid methylene blue or liquid methylene blue.

9 . The treatment device according to claim 1 , wherein the first conduit between the blood separation device and the dosing device includes a first shutoff valve, and the first conduit between the dosing device and the light treatment device includes a second shutoff valve.

10 . The treatment device according to claim 1 , wherein the dosing device comprises a plurality of dosing devices fluidly connected in parallel on the first conduit, each dosing device including a shutoff valve.

11 . The treatment device according to claim 1 , wherein the second conduit between the second transport pump and the light treatment device is fluidly connected to a buffer device.

12 . The treatment device according to claim 11 , wherein the second conduit between the light treatment device and the buffer device includes a shutoff valve and the second conduit between the buffer device and the second transport pump also includes a shutoff valve.

13 . The treatment device according to claim 1 , further comprising a liquid replenishing bag having an output port fluidly connected with an inlet of the second transport pump.

14 . The treatment device according to claim 13 , wherein a conduit between the liquid replenishing bag and the second transport pump includes a shutoff valve.

15 . The treatment device according to claim 1 , wherein the third transport pump is a two-way pump, and the third conduit is a two-way conduit.

16 . The treatment device according to claim 15 , wherein the third conduit includes a shutoff valve thereon.

17 . The treatment device according to claim 1 , further comprising a central control system that controls the transport pumps.

18 . The treatment device according to claim 1 , wherein the dosing device includes a medicine loading container having a hollow chamber and a medicine loading film, wherein the medicine loading film is located within the medicine loading container, and the medicine loading container includes an inlet and an outlet.

19 . The treatment device according to claim 18 , wherein the medicine loading container includes a lower bottom with an inlet and a corresponding upper bottom) with an outlet, and the medicine loading film is located at an inlet of the hollow chamber.

20 . A method of performing plasma virus inactivation, comprising:
flowing blood from a source through a first fluid conduit into a blood separation device; automatically separating the blood into plasma and a remaining portion; flowing the plasma from the blood separation device through a second fluid conduit and through a blood dosing device that doses an antiviral agent into the plasma; automatically flowing the plasma from the blood dosing device into an illumination pipeline of a light treatment device and illuminating the plasma using a light source coupled to the illumination pipeline; and transfusing the plasma to the source.

21 . The method of claim 20 , wherein the illumination pipeline forms a tortuous flow pathway.

22 . The method of claim 20 , further comprising adding a liquid from a replenishing container to the plasma after the plasma is illuminated.

Assignees

• Hope City

Inventors

• Yuwen Huang
• Qin Mo
• Bo Zhang
• Kaicheng Qian
• Yongming Zhu
• Xuerong Wang
• Xun Wang
• Xiaofei Wu
• Yao Jia
• Lidong Liu

Classifications

• A61M1/3496 Primary

  Plasmapheresis; Leucopheresis; Lymphopheresis (A61M1/3472 takes precedence) · CPC title

• A61M1/3455

  Substitution fluids · CPC title

• A61M1/3681

  by irradiation · CPC title

• A61M1/3403

  Regulation parameters · CPC title

• A61M1/3683

  using photoactive agents · CPC title